Lytix Biopharma CEO increases stake with share purchase

Lytix Biopharma AS's chief executive officer, Øystein Rekdal, acquired 10,000 shares in the company on December 11, 2025. The transaction took place on Euronext Growth Oslo at a price of NOK 9.9984 per share, totaling NOK 99,984.00. This mandatory notification of trade by a primary insider was made under the EU Market Abuse Regulation and the Norwegian Securities Trading Act.

Following this acquisition, Øystein Rekdal's total holdings in Lytix Biopharma AS have increased to 176,179 shares. The financial instrument involved was shares in Lytix Biopharma AS, identified by ISIN NO 0010405780. The company, based in Oslo, Norway, specializes in clinical-stage biotech with an oncolytic molecule platform.